Evaluation of Bone Gain Using Customized 3D Zirconia Barrier Versus Titanium Mesh
Launched by CAIRO UNIVERSITY · Aug 14, 2024
Trial Information
Current as of September 03, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how much bone can be gained using a specially designed 3D printed zirconia barrier compared to a traditional titanium mesh in patients with bone loss in a specific area of the jaw called the esthetic zone. The goal is to see which method is more effective in helping to rebuild the bone.
To participate in this study, individuals should be between 20 and 70 years old, have a narrow bone width of less than 4mm, and a vertical bone height of less than 9mm. They should also have healthy surrounding teeth and maintain good oral hygiene. Participants will need to commit to following post-operative care instructions and attend follow-up appointments. It is important to note that people with certain health issues, such as uncontrolled diabetes or infections in the area needing treatment, will not be eligible to join the trial. If you meet these criteria and are interested, you can expect to undergo a procedure that aims to improve your bone structure, which may ultimately benefit your dental health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age: 20-70 years.
- • Bone width less than 4mm
- • Vertical bone height less than 9mm
- • Periodontally sound neighboring teeth
- • Patients with sound vertical occlusal bite dimension
- • Good oral hygiene (full mouth plaque control record \[PCR\] \< 25%,full mouth bleeding on probing (BOP) \< 25% .
- • Patients demonstrating understanding and commitment to the post-operative care regime and the study follow up timeline.
- • Good general health (including participants with well-controlled systemic disease)
- Exclusion Criteria:
- • 1. Pathological lesions (abscess-cyst-acute infection) in the defect site
- • 2. Systemic diseases that would interfere with bone metabolism
- • 3. Uncontrolled diabetic patients
- • 4. Ongoing treatment or a history of recent chemotherapy or radiotherapy
- • 5. Poor oral hygiene after hygienic phase (Plaque control record over 30%) or Active periodontal disease
About Cairo University
Cairo University, a premier institution in Egypt, is dedicated to advancing medical research and education through innovative clinical trials. With a strong emphasis on improving healthcare outcomes, the university collaborates with various stakeholders to conduct rigorous scientific studies that address critical health challenges. Leveraging its extensive resources and expert faculty, Cairo University aims to contribute valuable insights to the medical community and enhance patient care both locally and globally. Through its commitment to ethical research practices and excellence, the university plays a pivotal role in shaping the future of healthcare in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cairo, , Egypt
Patients applied
Trial Officials
Hani El Nahass
Study Director
Cairo University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported